Table 1 Demographic, anthropometric and HIV variables in the GEPPO cohort
Total n = 1573 | HIV-negative vs HIV-positive | HIV-negative | HIV-positive | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
HIV- (n = 315, 20·03%) | HIV+ (n = 1258, 79·97%) | p | 65–74 years (n = 224, 71·11%) | ≥ 75 years (n = 91, 28·89%) | p | 65–74 years (n = 965, 76·71%) | ≥ 75 years (n = 293, 23·29%) | p | ||
Variable | Mean (SD) [sample size] | Mean (SD/%) [sample size] | Mean (SD/%) [sample size] | Mean (SD/%) [sample size] | ||||||
Gender (F) | 271 (17.23%) [1573] | 66 (20.95%) [315] | 205 (16.3%) [1258] | 0.06 * | 42 (18.75%) [224] | 24 (26.37%) [91] | 0·18 * | 155 (16.06%) [965] | 50 (15.06%) [293] | 0.75 * |
Female Age | 71.23 (3.94) [271] | 71.55 (3.42) [66] | 71.15 (4.05) [205] | 0.12 *** | 69.83 (2.48) [182] | 77.46 (2.08) [67] | < 0.01*** | 69.46 (2.52) [810] | 77.5 (2.0) [243] | < 0.01*** |
Male Age | 71.71 (4.27) [1302] | 72.61 (4.37) [249] | 71.42 (4.21) [1053] | 0.06 *** | 70.05 (2.75) [42] | 75.61 (0.49) [25] | < 0.01*** | 69.35 (2.48) [155] | 77.17 (1.) [50] | < 0.01*** |
BMI | 26.55 (8.59) [1224] | 28.65 (4.18) [301] | 25.87 (9.5) [923] | < 0.01 *** | 28.71 (4.04) [8] | 28.52 (4.54) [6] | 0.65 *** | 26.15 (10.66) [264] | 24.98 (3.95) [71] | 0.04 *** |
Current smoker | 313 (23.29%) [1344] | 42 (14.24%) [295] | 271 (25.83%) [1049] | < 0.01* | 33 (15.57%) [212] | 9 (10.84%) [83] | 0.39 * | 234 (29.03%) [806] | 37 (15.23%) [243] | < 0.01* |
HIV duration (years) | NA | NA | 17.17 (7.65) [1240] | NA | NA | NA | NA | 17.24 (7.76) [949] | 16.92 (7.3) [291] | 0·64 ** |
< 10 years | NA | NA | 263 (21.23%) [1240] | NA | NA | NA | NA | 200 (21·07%) [949] | 63 (21.72%) [291] | 0·9* |
10–20 years | NA | NA | 561 (45.28%) [1240] | NA | NA | NA | NA | 433 (45.63%) [949] | 128 (44.14%) [291] | |
> 20 years | NA | NA | 415 (33.49%) [1240] | NA | NA | NA | NA | 316 (33.3%) [949] | 99 (34.14%) [291] | |
CD4 nadir | NA | NA | 197.5 (84–310) [1240] | NA | NA | NA | NA | 200 (89.75–308) [949] | 191 (74.75–320) [291] | 0·61 ** |
Current CD4 | NA | NA | 644.58 (1240) [1258] | NA | NA | NA | NA | 651.23 (290.95) [949] | 622.55 (282) [291] | 0·18 ** |
CD4/CD8 | NA | NA | 0.97 (1.45) [1240] | NA | NA | NA | NA | 0.92 (0.8) [949] | 1.13 (2.63) [291] | 0·28 *** |
Viral load ≤40 | NA | NA | 1044 (94.31%) [1107] | NA | NA | NA | NA | 812 (94.97%) [855] | 232 (92.06%) [252] | 0.11 * |
Viral load undetectable | NA | NA | 925 (86.53%) [1068] | NA | NA | NA | NA | 712 (86.72%) [821] | 213 (85.89%) [248] | 0.82 * |
HBV co-infection | NAv | NAv | 103 (9.83%) [1048] | NAv | NAv | NAv | NAv | 84 (10.51%) [799] | 19 (7.63%) [249] | 0·23* |
HCV co-infection | NAv | NAv | 141 (12.57%) [1121] | NAv | NAv | NAv | NAv | 113 (13·11%) [862] | 28 (10·77%) [259] | 0·12 * |
Age at HIV diagnosis | NA | NA | 54·03 (8.83) [1239] | NA | NA | NA | NA | 52·11 (8.28) [949] | 60·3 (7.6) [290] | < 0·01*** |
Triple/M ART | NA | NA | 390 (31.91%) [1222] | NA | NA | NA | NA | 312 (31.01%) [1006] | 78 (36.11%) [216] | 0·17 * |
Mono/dual ART | NA | NA | 832 (68.09%) [1221] | NA | NA | NA | NA | 694 (68.99%) [1006] | 138 (63.89%) [215] | |